May 24, 2019 / 7:08 PM / a month ago

BRIEF-FDA Approves Zolgensma To Treat Pediatric Patients With Spinal Muscular Atrophy

May 24 (Reuters) - Novartis AG:

* FDA APPROVES INNOVATIVE GENE THERAPY TO TREAT PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY, A RARE DISEASE AND LEADING GENETIC CAUSE OF INFANT MORTALITY

* FDA - ZOLGENSMA HAS A BOXED WARNING THAT ACUTE SERIOUS LIVER INJURY CAN OCCUR

* FDA- ZOLGENSMA IS INDICATED FOR TREATMENT OF CHILDREN LESS THAN TWO YEARS OF AGE WITH SMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below